Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 9:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 161 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Geriatric Syndromes Clear all
Withdrawn Phase 1 Interventional

A PK and Safety Evaluation of HORIZANT (Gabapentin Enacarbil) in Adolescents With Moderate-to-Severe Primary RLS

NCT02633657
View directory record Official record
Conditions
RLS
Interventions
HORIZANT 300 mg
Drug
Lead sponsor
XenoPort, Inc.
Industry
Eligibility
13 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
4
States / cities
Redwood City, California • St Louis, Missouri • Columbia, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2021 · Synced Oct 21, 2026, 9:52 AM EDT
Completed Phase 2 Interventional Results available

Use of β-hydroxy-β-methylbutyrate to Counteract Muscle Loss in Men With Prostate Cancer on Androgen Ablation

NCT01607879
View directory record Official record
Conditions
Prostate Cancer
Interventions
Standard of care ADT + (HMB + arginine + glutamine), Standard of care ADT
Drug · Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
60 Years and older · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 22, 2023 · Synced Oct 21, 2026, 9:52 AM EDT
Terminated Phase 2 Interventional

A Study of RO5186582 in Down Syndrome Among Children 6 to 11 Years of Age

NCT02484703
View directory record Official record
Conditions
Down Syndrome
Interventions
Placebo, RO5186582
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
6 Years to 11 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
9
States / cities
Phoenix, Arizona • Decatur, Georgia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2017 · Synced Oct 21, 2026, 9:52 AM EDT
Completed Phase 2 Interventional Results available

Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS

NCT00334074
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Myelodysplastic Syndromes, Chronic Myelogenous Leukemia
Interventions
Clofarabine and Cytarabine
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 17, 2013 · Synced Oct 21, 2026, 9:52 AM EDT
Completed Phase 2 Interventional

A Study Evaluating NPT 2042 Versus Placebo in Subjects Aged 16-75 Years With Genetic Generalized Epilepsy (GGE) and Absence Seizures

NCT06769659
View directory record Official record
Conditions
Epilepsy, Generalized, Epilepsy, Absence
Interventions
NPT 2042, Placebo
Drug · Other
Lead sponsor
NeuroPro Therapeutics, Inc.
Industry
Eligibility
16 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 21, 2026, 9:52 AM EDT
Completed Phase 3 Interventional

A Study of BPN14770 in Male Adults (Aged 18 to 45) With Fragile X Syndrome

NCT05358886
View directory record Official record
Conditions
Fragile X Syndrome
Interventions
BPN14770/ zatolmilast, Placebo
Drug
Lead sponsor
Tetra Discovery Partners
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
17
States / cities
Irvine, California • Orange, California • Sacramento, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 21, 2026, 9:52 AM EDT
Terminated Not applicable Interventional Results available

Expanding Access to Comprehensive Geriatrics Care Via Telehealth

NCT05166603
View directory record Official record
Conditions
Geriatric Syndrome
Interventions
TeleGRACE
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
70 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 22, 2024 · Synced Oct 21, 2026, 9:52 AM EDT
Completed No phase listed Observational

Comparative Pharmacokinetics (PK) Study of Efavirenz or Lopinavir/Ritonavir Between Older and Younger HIV-Infected Adults

NCT00179335
View directory record Official record
Conditions
HIV Infections
Interventions
Blood drawing to determine drug levels
Procedure
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 26, 2021 · Synced Oct 21, 2026, 9:52 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Wild Blueberries and Cardiovascular Health in Middle-aged/Older Men and Postmenopausal Women

NCT04530916
View directory record Official record
Conditions
Hypertension, Aging, Endothelial Dysfunction, Men
Interventions
Blueberry Powder, Placebo Powder
Dietary Supplement
Lead sponsor
Colorado State University
Other
Eligibility
45 Years to 70 Years · Male only
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 21, 2026, 9:52 AM EDT
Terminated Phase 2 Interventional

Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

NCT00666497
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
Interventions
Azacitidine, MGCD0103
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
60 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2015 · Synced Oct 21, 2026, 9:52 AM EDT
Terminated No phase listed Observational

Using Walk With Ease Walking Program With Men 65 and Older Being Treated for Prostate Cancer

NCT02139774
View directory record Official record
Conditions
Prostate Cancer
Interventions
Walk with Ease
Behavioral
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
65 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 4, 2015 · Synced Oct 21, 2026, 9:52 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years

NCT00799864
View directory record Official record
Conditions
HIV-1
Interventions
Rilpivirine, Zidovudine, Abacavir, Tenofovir disoproxil fumarate, Lamivudine, Emtricitabine
Drug
Lead sponsor
Janssen Sciences Ireland UC
Industry
Eligibility
6 Years to 17 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
2
States / cities
Syracuse, New York • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Oct 21, 2026, 9:52 AM EDT
Terminated Phase 2 Interventional Results available

Study in Pediatric Subjects With Epilepsy

NCT01494584
View directory record Official record
Conditions
Epilepsy
Interventions
ezogabine/retigabine
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years to 17 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
4
States / cities
Los Angeles, California • Wellington, Florida • Memphis, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2020 · Synced Oct 21, 2026, 9:52 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Trial of Solriamfetol in the Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

NCT04622293
View directory record Official record
Conditions
Chronic Fatigue Syndrome, Myalgic Encephalomyelitis
Interventions
Solriamfetol Oral Tablet [Sunosi], Placebo
Drug
Lead sponsor
Rochester Center for Behavioral Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Rochester Hills, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 6, 2025 · Synced Oct 21, 2026, 9:52 AM EDT
Completed Not applicable Interventional

Improving Frailty With a Rigorous Ambulation Intervention in Lung Transplant Patients

NCT03636412
View directory record Official record
Conditions
Transplant-Related Disorder, Frail Elderly Syndrome, Sarcopenia, Lung Graft Dysfunction, Mobility Limitation
Interventions
Ambulation
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Oct 21, 2026, 9:52 AM EDT
Active, not recruiting Phase 2 Interventional

Study of a Geriatric Assessment to Plan a Treatment Approach for Older People With Various Blood Disorders

NCT04761770
View directory record Official record
Conditions
Myelodysplastic Syndrome, Myeloproliferative Neoplasms, Chronic Myelomonocytic Leukemia, Atypical Chronic Myeloid Leukemia, Myelodysplastic/Myeloproliferative Overlapping Syndrome
Interventions
Geriatric assessment (GA) pre-transplant, conditioning regimen, Allogeneic CD34+ selected stem cells
Other · Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
60 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 21, 2026, 9:52 AM EDT
Recruiting Not applicable Interventional

A Telehealth Advance Care Planning Intervention

NCT05875805
View directory record Official record
Conditions
Myeloid Malignancy, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm, Myelofibrosis
Interventions
Telehealth Serious Illness Care Program, Education Control
Behavioral · Other
Lead sponsor
University of Rochester
Other
Eligibility
60 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 21, 2026, 9:52 AM EDT
Terminated Phase 2 Interventional

MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease

NCT00374296
View directory record Official record
Conditions
Myelogenous Leukemia, Acute, Myelodysplastic Syndromes
Interventions
MGCD0103
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
6
States / cities
Kansas City, Missouri • Rochester, New York • Canton, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2015 · Synced Oct 21, 2026, 9:52 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Aging, Geriatric Syndromes and Clonal Hematopoiesis

NCT02604563
View directory record Official record
Conditions
Geriatrics, Aged, Geriatric Syndromes, Cardiovascular Diseases
Interventions
Cognitive Assessment, Activities of Daily Living Questionnaire, Instrumental Activities of Daily Living, subscale of the OARS, Karnofsky Self-reported Performance Rating Scale, Number of Falls, Physical Health Section, subscale of the OARS, MOS Social Activity Survey, Unintentional Weight Loss, Peripheral Blood Draw, Buccal Swab, Heart Health and Smoking History from BRFSS questionnaire, Gait Speed, Grip Strength, Height and Weight measurements, Blood pressure measurement, Optional bone marrow biopsy, Blood draw for trauma measurements, Femur head donation, Knee bone fragments, Bone marrow aspirate
Other · Genetic · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
50 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2030
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 21, 2026, 9:52 AM EDT
Completed Phase 3 Interventional Results available

Study in Pediatrics With HypEREosinophilic Syndrome (SPHERE)

NCT04965636
View directory record Official record
Conditions
Hypereosinophilic Syndrome
Interventions
Mepolizumab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Years to 17 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
4
States / cities
Rochester, Minnesota • Cincinnati, Ohio • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 21, 2026, 9:52 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of L-citrulline Supplementation on Vascular Function in Metabolic Syndrome

NCT06025357
View directory record Official record
Conditions
Metabolic Syndrome, Menopause
Interventions
L-Citrulline supplementation, Placebo
Dietary Supplement
Lead sponsor
Texas Tech University
Other
Eligibility
45 Years to 79 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Oct 21, 2026, 9:52 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Cellular Senescence and COVID-19 Long-Hauler Syndrome

NCT04903132
View directory record Official record
Conditions
SARS-CoV2 Infection
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 21, 2026, 9:52 AM EDT
Not listed Phase 1Phase 2 Interventional

Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)

NCT01211457
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions
sapacitabine and decitabine (Part 1 - completed), sapacitabine and venetoclax (Part 2 - recruiting)
Drug
Lead sponsor
Cyclacel Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
3
States / cities
Chicago, Illinois • Buffalo, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2019 · Synced Oct 21, 2026, 9:52 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant

NCT02038153
View directory record Official record
Conditions
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia in Remission
Interventions
Laboratory Biomarker Analysis, Lenalidomide
Other · Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
60 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
The Bronx, New York • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 14, 2020 · Synced Oct 21, 2026, 9:52 AM EDT